Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

BTA-C585 shows excellent pharmacokinetic and safety profile in animal studies

Oct. 3, 2014

XenoPort presents pharmacokinetic data for XP-23829

Oct. 3, 2014

Phase I/II first-in-human results presented for lucitanib

Oct. 3, 2014

Novel candidates for neuropathic pain prepared at Nippon Chemiphar

Oct. 2, 2014

Model of autoimmune optic neuritis used to assess new treatment strategy

Oct. 2, 2014

Phase II data presented in patients with CMV and adenovirus resistance profiles

Oct. 2, 2014

Preclinical profile of basimglurant described

Oct. 2, 2014

New mTOR inhibitors discovered at Sanofi

Oct. 2, 2014

ADN-3662 demonstrates activity in well-recognized in vivo models of mood deficits

Oct. 2, 2014

Preliminary phase I data demonstrates safety of intravitreal AAV2-sFLT01 in patients with AMD

Oct. 1, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...